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Abstract: MTHFD1 is a trifunctional protein containing 10-formyltetrahydrofolate synthetase,
5,10-methenyltetrahydrofolate cyclohydrolase and 5,10-methylenetetrahydrofolate
dehydrogenase activities. It is encoded by  MTHFD1  and functions in the cytoplasmic
folate cycle where it is involved in  de novo  purine synthesis, synthesis of thymidylate
and remethylation of homocysteine to methionine. Since the first reported case of
severe combined immunodeficiency resulting from  MTHFD1  mutations, seven
additional patients ascertained through molecular analysis have been reported with
variable phenotypes, including megaloblastic anemia, atypical hemolytic uremic
syndrome, hyperhomocysteinemia, microangiopathy, infections and autoimmune
diseases. We determined the level of MTHFD1 expression and dehydrogenase
specific activity in cell extracts from cultured fibroblasts of three previously reported
patients, as well as a patient with megaloblastic anemia and recurrent infections with
compound heterozygous  MTHFD1  variants that were predicted to be deleterious.
MTHFD1 protein expression determined by Western blotting in fibroblast extracts from
three of the patients was markedly decreased compared to expression in wild type
cells (between 4.8 and 14.3 percent of mean control values). MTHFD1 expression in
the fourth patient was approximately 44% of mean control values. There was no
detectable methylenetetrahydrofolate dehydrogenase specific activity in extracts from
any of the four patients. This is the first measurement of MTHFD1 function in MTHFD1
deficient patients and confirms the previous molecular diagnoses.
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 MTHFD1 is a trifunctional protein containing 10-formyltetrahydrofolate synthetase, 
5,10-methenyltetrahydrofolate cyclohydrolase and 5,10-methylenetetrahydrofolate 
dehydrogenase activities. It is encoded by MTHFD1 and functions in the cytoplasmic 
folate cycle where it is involved in de novo purine synthesis, synthesis of thymidylate 
and remethylation of homocysteine to methionine. Since the first reported case of 
severe combined immunodeficiency resulting from MTHFD1 mutations, seven additional 
patients ascertained through molecular analysis have been reported with variable 
phenotypes, including megaloblastic anemia, atypical hemolytic uremic syndrome, 
hyperhomocysteinemia, microangiopathy, infections and autoimmune diseases. We 
determined the level of MTHFD1 expression and dehydrogenase specific activity in cell 
extracts from cultured fibroblasts of three previously reported patients, as well as a 
patient with megaloblastic anemia and recurrent infections with compound 
heterozygous MTHFD1 variants that were predicted to be deleterious. MTHFD1 protein 
expression determined by Western blotting in fibroblast extracts from three of the 
patients was markedly decreased compared to expression in wild type cells (between 
4.8 and 14.3 percent of mean control values). MTHFD1 expression in the fourth patient 
was approximately 44% of mean control values. There was no detectable 
methylenetetrahydrofolate dehydrogenase specific activity in extracts from any of the 
four patients. This is the first measurement of MTHFD1 function in MTHFD1 deficient 
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PBS – phosphate buffered saline 
TBST – Tris buffered saline with Tween-20 
TCA – trichloroacetic acid 






MTHFD1 (MIM 172460) encodes a protein that contains three distinct enzyme activities: 
10-formyltetrahydrofolate synthetase (EC 6.3.4.3), 5,10-methenyltetrahydrofolate 
cyclohydrolase (EC 3.5.4.9) and 5,10-methylenetetrahydrofolate dehydrogenase (EC 
1.5.1.5). These activities catalyze three sequential reactions in cytoplasmic one-carbon 
metabolism that generate derivatives of tetrahydrofolate used as one-carbon sources in 
biosynthetic processes occurring in the cytoplasm [1,2] including de novo purine 
synthesis, thymidylate synthesis, and remethylation of homocysteine to methionine. 
MTHFD1 has also been shown to translocate to the nucleus during S-phase [3] as well 
as during folate or MTHFD1 deficiency [4], suggesting a critical role of MTHFD1 for de 
novo nuclear thymidylate synthesis and a mechanism by which MTHFD1 deficiency can 
lead to megaloblastic anemia [4]. Two major domains confer the trifunctional enzymatic 
activity of MTHFD1: an amino-terminal domain containing the dehydrogenase and 
cyclohydrolase activities, and a larger C-terminal synthetase domain [5].  MTHFD1 
clearly plays an essential role in cellular function as homozygous knockout mutations in 
Mthfd1 are embryonic lethal in mice [6,7].  
 
Since the first reported case of severe combined immunodeficiency (SCID) associated 
with variants in MTHFD1 [8,9], seven additional patients have been reported [10-12]. All 
patients had compound heterozygous variants in MTHFD1 except one with a 
homozygous variant identified in a population-based newborn screen for SCID in Saudi 
Arabia [12]. In addition to variable phenotypes of SCID, clinical manifestations of 
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MTHFD1 deficiency include megaloblastic anemia (common to all MTHFD1 deficiency 
patients reported thus far), atypical hemolytic uremic syndrome, anisocytosis, 
autoimmune diseases and microangiopathy. The highly variable clinical phenotypes 
caused by pathogenic MTHFD1 variants may be the result of variable degrees of 
residual function of its constituent activities.  
 
All reported cases of MTHFD1 deficiency have been diagnosed by the identification of 
likely causal variants by exome or targeted sequencing. Biochemical characterization of 
cultured fibroblasts derived from three patients showed decreased synthesis of 
methionine from labeled formate and mildly reduced levels of methylcobalamin (MeCbl) 
[8,10]. These findings likely reflect decreased provision of 5-methyltetrahdrofolate, 
necessary for MeCbl synthesis, due to decreased MTHFD1 function.  Direct assay of 
MTHFD1 enzyme activities in patient fibroblasts has not been reported. We have 
measured methylenetetrahydrofolate dehydrogenase protein levels and specific activity 
in human fibroblast extracts and have demonstrated that these are deficient in patients 
with a diagnosis of MTHFD1 deficiency based on gene sequencing. 
 
 
2. Materials and methods 
 
2.1 Patients  
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Clinical and molecular findings in Patient 1 [8,9] as well as Patients 2 and 3 [10] have 
been previously reported. Patients 1 to 3 are numbered as in the publication of Burda et 
al [10]. The clinical history of Patient 4 has also been previously been reported although 
the MTHFD1 variants were detected later by exome sequencing [13]. She is a 34-year-
old woman with megaloblastic anemia at 6 months of life, related to cobalamin 
deficiency caused by a heterozygous GIF variant coupled with a heterozygous FUT2 
variant [13]. The anemia responded to therapy with cobalamin in the absence of folate 
treatment. She has a history of immunodeficiency from infancy with recurrent lung 
infections that responded partially to treatment with immunoglobulin. She also had milk 
intolerance. Since the immunodeficiency did not fit the diagnosis of cobalamin 
deficiency, she underwent exome sequencing which identified compound heterozygous 
variants in MTHFD1. The MTHFD1 variants identified in the four patients are 
summarized in Table 1. 
 
The first variant in Patient 4, NM_005956.4:c.146C>T (p.Ser49Phe) is listed as likely 
pathogenic in ClinVar (ClinVar ID: 446306) [14] and affects a highly conserved residue 
in the NADP-binding site of the dehydrogenase/cyclohydrolase catalytic site. It has 
previously been shown to segregate with disease in trans with a known pathogenic 
variant, NM_005956.4:c.673G>T (p.Glu225Ter) (ClinVar ID: 446307) in multiple 
affected individuals [10,15], and in silico prediction tools consistently consider this 
variant as deleterious (PolyPhen2, SIFT, GERP, and CADD scores), which has been 
confirmed experimentally [10]. The second variant, NM_005956.4:c.826G>C 
(p.Gly276Arg) has not been previously reported. It is a rare variant not present in the 
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population database gnomAD, a repository of sequencing data from over 140,000 
seemingly healthy adults [16], and other sequencing data repositories. It affects a highly 
conserved residue in the dehydrogenase catalytic site [17] and in silico prediction tools 
consistently consider this variant as deleterious (PolyPhen2, SIFT, GERP, and CADD 
scores). Segregation analysis revealed both variants to segregate with disease in her 
affected brother. Moreover, these variants are in trans with her sibling having the 
identical genotype, while her mother was found to be heterozygous for this novel 
variant. Her father was unavailable for testing. 
 
2.2 Cell Culture 
 
Patient-derived and control fibroblasts were maintained at 37°C and 5% CO2 in modified 
Eagle’s minimum essential medium with non-essential amino acids supplemented with 
5% fetal bovine serum and 5% iron-enriched bovine calf serum (Wisent Bio Products). 
 
2.3 Western Blotting 
 
Confluent fibroblasts in 175 cm2 tissue culture flasks were washed with phosphate 
buffered saline (PBS), trypsinized, pelleted and stored at -80°C until used. Pellets were 
suspended in RIPA lysis buffer (PBS containing 1% IGEPAL CA-630 (Sigma-Aldrich), 
0.5% sodium deoxycholate and 0.1% SDS) containing 1x Pierce Protease Inhibitor Mix 
(EDTA-free; Thermo Fisher Scientific), incubated on ice for 20 minutes and centrifuged 
at 4°C for 15 minutes at 13,000 x g. Supernatants where mixed with 4x Laemmli 
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Sample Buffer (Bio-Rad Laboratories) and heated at 95°C for 5 minutes before storage 
at -80°C. Protein content of extracts was determined by the Lowry assay with bovine 
serum albumin (BSA) as a standard [18]. 
 
Twenty-five µg aliquots of cell extract from patient and control fibroblasts were loaded 
onto 10% SDS-polyacrylamide gels, run at 100 volts for 1.5 hours in Tris/glycine buffer 
pH 8.3 (25 mmol/L Tris, 192 mmol/L glycine) containing 0.1% SDS, and transferred to 
nitrocellulose membrane for 1 hour at 100 volts in Tris/glycine buffer containing 10% 
methanol. The membrane was cut into two and incubated with 5% milk blocking solution 
for 1 hour. After washing with 1x Tris buffered saline containing 0.05% Tween-20 
(TBST), membrane halves were incubated overnight with either rabbit anti-MTHFD1 
(1:2000 dilution, [19]) or anti-β-actin (1:5000 dilution, Cell Signaling Technology) 
antibodies. The MTHFD1 antibody was generated using purified preparations of the 
entire intact mouse MTHFD1 protein, which is 93.2% identical/97% homologous to 
human MTHFD1. This antibody has been used previously to detect the human protein 
in Mthfd1-/- cells transfected with human MTHFD1 cDNA (unpublished data). The 
membranes were then washed with TBST, incubated with Goat-Anti-Rabbit IgG HRP-
conjugate (Bio-Rad Laboratories) visualized by chemiluminescence using Pierce ECL 
Western blotting substrate (ThermoFisher Scientific) following manufacturer’s 
instructions, and documented with an Amersham Imager 600. Protein expression was 
quantified using Amersham Imager 600 Analysis Software version 1.0 (GE Healthcare 
Life Sciences). MTHFD1 expression was normalized to β-actin expression in the same 
lane of the gel, to compensate for differences in protein loading in different lanes. 
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Patient MTHFD1 values were expressed as a percentage of control MTHFD1 
expression on the same blot. 
 
2.4 Methylenetetrahydrofolate Dehydrogenase Assay 
 
Pelleted cells were resuspended in 300 µL of extraction buffer (0.1mol/L potassium 
phosphate pH 7.3; 0.04x of Pierce Protease Inhibitor mix, EDTA-free; 35.3 mmol/L β-
mercaptoethanol) and sonicated on ice using a small long probe. Sonication comprised 
of five 10-second pulses with one-minute pauses between pulses. A 0.24x volume of 
glycerol was added and the mixture was centrifuged at 9,300 x g for 10 minutes at room 
temperature. The supernatant was transferred to a fresh tube and stored at -80°C until 
used. Protein content of the lysate was determined using a Lowry Assay with BSA as a 
standard [18]. 
 
Methylenetetrahydrofolate dehydrogenase activity was determined by measuring the 
optical density (OD) of the methenyltetrahydrofolate reaction product at 350 nm [20].  
Assays were performed in triplicate for each cell line, with one blank. 250 μg (20 to 
35μL) of cell extract was added at time 0 to a 500 µL reaction mixture comprised of 0.1 
mmol/L potassium phosphate pH 7.3, 0.144 mol/L β-mercaptoethanol, 0.2 mmol/L 
tetrahydrofolate trihydrochloride (Schirks Laboratories, Jona, Switzerland), 2.3 mmol/L 
formaldehyde, 0.17 mg/mL NADP+ at 30°C. The reaction was terminated after 30 
minutes by adding an equal volume of 7% trichloroacetic acid (TCA). Blanks were 
prepared by adding the cell extract to the reaction mix after the TCA.  
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Lactate dehydrogenase activity was measured on a Beckman AU5800 analyzer in the 







3.1 MTHFD1 Expression 
 
Western blotting demonstrated markedly reduced levels of MTHFD1 protein compared 
to controls in Patients 1 and 2; levels in Patient 3 were lower than in controls but 
somewhat higher than in the other patients (Figure 1). Quantification of MTHFD1 protein 
levels, expressed as a percentage of control values on the same blot, were 5.4% and 
7.2% (replicate experiments) for Patient 1, 4.8% and 5.1% for Patient 2, 13.9% and 
14.3% for Patient 3, and 46% and 41.6% for Patient 4 (Table 2). MTHFD1 expression in 
the mother of Patient 4 was similar to that in her daughter (38.8% and 39.2%).  
 
3.2 Methylenetetrahydrofolate Dehydrogenase Activity 
 
Methylenetetrahydrofolate dehydrogenase activity was not detected in fibroblast 
extracts of patients 1, 2, 3 and 4 (Table 2). Extracts from the mother of patient 4 showed 
an intermediate level of dehydrogenase specific activity (38-54% of wild type specific 
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activity). Lactate dehydrogenase specific activity in equal volumes of fibroblast extracts 







MTHFD1 encodes a cytosolic trifunctional enzyme that catalyzes the condensation of 
mitochondria-derived formate with tetrahydrofolate to form 10-formyltetrahydrofolate 
(10-formyltetrahydrofolate synthetase activity), and its sequential conversion to 5,10-
methenyltetrahydrofolate (5,10-methenyltetrahydrofolate cyclohydrolase) and 5,10-
methylenetetrahydrofolate (5,10-methylenetetrahydrofolate dehydrogenase), generating 
one-carbon units required for de novo purine biosynthesis, thymidylate synthesis and 
remethylation of homocysteine to form methionine [1,2]. In all reports of patients with 
MTHFD1 deficiency, diagnosis has been achieved by sequencing studies that identified 
presumably causal MTHFD1 variants in individuals with clinical findings consistent with 
the disorder (generally megaloblastic anemia and SCID). Somatic cell studies in 
Patients 1, 2 and 3 have shown decreased incorporation of label from [14C]formate into 
methionine, and decreased synthesis of methylcobalamin from exogenous 
cyanocobalamin in  fibroblasts [8,10], reflecting reduced provision of its precursor 5,10-
methylenetetrahydrofolate. In a study of fibroblasts from Patient 1, there was evidence 
of decreased thymidylate synthesis and homocysteine remethylation in the presence of 
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normal purine biosynthesis, reflecting relative sparing of 10-formyltetrahydrofolate 
synthetase activity in this individual [4]. However, specific activity of MTHFD1 has not 
been measured for any of the reported patients. 
 
In the present study, we investigated expression of the MTHFD1 protein and measured 
the specific activity of its 5,10-methylentetrahydrofolate dehydrogenase component in 
fibroblasts from four MTHFD1 deficient patients (three previously reported patients and 
one new patient). We found variably decreased MTHFD1 protein levels and no 
detectable dehydrogenase activity. These results represent the first direct 
demonstration of decreased MTHFD1 function in patients with this disorder, and support 
the previous molecular diagnoses.  In Patients 1 and 2, MTHFD1 expression was 
markedly reduced (5-7% and 4-5% of control MTHFD1expression, respectively) as 
determined by Western blotting analysis. This in itself can explain the lack of 
dehydrogenase function in patient extracts. MTHFD1 expression was somewhat higher 
in Patient 3 (13-14% of controls), who carried a nonsense variant in trans with a 
missense variant  located in the NADP+ binding site of the dehydrogenase active site 
[10]. MTHFD1 expression was also higher (41-46% of controls) in Patient 4; both 
variants in this individual were predicted to affect the dehydrogenase/cyclohydrolase 
domain of the protein and not MTHFD1 expression. This suggests that the missense 
variants in Patients 3 and 4 resulted in expression of protein forms that retained no 
dehydrogenase activity. 
 
In addition to the SCID phenotype, Patient 4 had megaloblastic anemia, which appears 
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to be a hallmark of MTHFD1 deficiency. However, the anemia was primarily caused by 
the patient’s cobalamin deficiency, which was related to decreased secretion and 
fucosylation of gastric intrinsic factor [13]. Although Patient 4 shares a heterozygous 
MTHFD1 variant with Patient 3 and her siblings, their phenotypes and degree of 
severity differ. This may be due in part to the differences in the residual amounts of the 
three MTHFD1 activities contributed by the other MTHFD1 allele in these individuals. 
Patient 4’s brother carries the same compound heterozygous MTHFD1 mutations and 
shows similar immunological phenotypes to Patient 4. Consistent with our predictions, 
the mother of Patient 4 with no clinical manifestations of MTHFD1 deficiency is 
heterozygous for the novel NM_005956.4:c.826G>C (p.Gly276Arg) MTHFD1 variant 
and shows a dehydrogenase specific activity that is roughly half of wild type level. 
 
The enzyme assay was effective at identifying a lack of methylenetetrahydrofolate 
dehydrogenase activity in each of the patients that we tested. Evaluation of patients with 
partial dehydrogenase activity will require experimental establishment of a reference 
range, as the mother of Patient 4 is heterozygous for the novel MTHFD1 variant, shows 
no clinical manifestations of MTHFD1 deficiency and has a dehydrogenase specific 
activity that is roughly half of wild type level.  
 
As a first step to defining the relationship between enzyme activity and deleterious 
variants in MTHFD1, we have demonstrated that cells from patients with a number of 
different variants have a decrease in the quantity and activity of the enzyme. As new 
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variants continue to be identified by genomics, these assays will be invaluable in their 
assessment and classification. 
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Figure 1: Western blot analysis of MTHFD1 expression 
 
Ten percent SDS-PAGE of 25 µg of cell extracts from four control fibroblast lines, and 
four MTHFD1 patients (Patient 1 to 4), as well as the mother (of Patient 4). Upper band 
(black arrow) represents MTHFD1. Quantification of bands is shown in Table 2 (Extract 
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Table 2: Protein expression and methylenetetrahydrofolate dehydrogenase specific 
activity in two independently extracted fibroblast extracts. MTHFD1 protein expression 
in patient fibroblast extracts is expressed as a percentage of MTHFD1 protein levels in 
control cells on the same blot. MTHFD1 dehydrogenase (nmole/min/mg) after 30 
minutes incubation at 30 °C in reported patients (Patient 1 to Patient 3), referred patient 
(Patient 4), mother of patient 4 and control wild type fibroblasts (MCH23). nd = not 
detected. The range of specific activity of MTHFD1 dehydrogenase in six independently 
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extracted and tested fibroblast extracts from a wild type control (MCH23) was 0.83 to 
1.35 nmole/min/mg with a mean specific activity of 1.14 nmole/min/mg and a standard 
deviation of 0.17. All data points in MTHFD1 dehydrogenase specific activity are mean 
of triplicate experiments. Reported MTHFD1 dehydrogenase specific activity in wild type 
human fibroblasts is 1.25 nmole/min/mg [21] 
 
 
